Inhibition of Ca2+/Calmodulin-dependent protein kinase II reverses oxaliplatin-induced mechanical allodynia in Rats by Shirahama, Masafumi et al.
RESEARCH Open Access
Inhibition of Ca
2+/Calmodulin-dependent protein
kinase II reverses oxaliplatin-induced mechanical
allodynia in Rats
Masafumi Shirahama, Soichiro Ushio, Nobuaki Egashira
*, Shota Yamamoto, Hikaru Sada, Ken Masuguchi,
Takehiro Kawashiri and Ryozo Oishi
Abstract
Background: Oxaliplatin is a key drug in the treatment of colorectal cancer, but it causes severe peripheral
neuropathy. We previously reported that oxaliplatin (4 mg/kg, i.p., twice a week) induces mechanical allodynia in
the late phase in rats, and that spinal NR2B-containig N-methyl-D-aspartate (NMDA) receptors are involved in the
oxaliplatin-induced mechanical allodynia. In the present study, we investigated the involvement of Ca
2+/calmodulin
dependent protein kinase II (CaMKII), which is a major intracellular protein kinase and is activated by NMDA
receptor-mediated Ca
2+ influx, in the oxaliplatin-induced mechanical allodynia in rats.
Results: An increase of CaMKII phosphorylation was found in the spinal cord (L4-6) of oxaliplatin-treated rats. This
increased CaMKII phosphorylation was reversed by intrathecal injection of a selective CaMKII inhibitor KN-93 (50
nmol, i.t.) and a selective NR2B antagonist Ro 25-6981 (300 nmol, i.t.). Moreover, acute administration of KN-93 (50
nmol, i.t.) strongly reversed the oxaliplatin-induced mechanical allodynia in von Frey test, while it did not affect the
oxaliplatin-induced cold hyperalgesia in acetone test. Similarly, oral administration of trifluoperazine (0.1 and 0.3
mg/kg, p.o.), which is an antipsychotic drug and inhibits calmodulin, reduced both mechanical allodynia and
increased CaMKII phosphorylation. On the other hand, trifluoperazine at the effective dose (0.3 mg/kg) had no
effect on the paw withdrawal threshold in intact rats. In addition, trifluoperazine at the same dose did not affect
the motor coordination in rota-rod test in intact and oxaliplatin-treated rats.
Conclusions: These results suggest that CaMKII is involved in the oxaliplatin-induced mechanical allodynia,
and trifluoperazine may be useful for the treatment of oxaliplatin-induced peripheral neuropathy in clinical
setting.
Background
Oxaliplatin, a platinum-based chemotherapeutic agent,
has widely been used for colorectal cancer. However,
oxaliplatin causes severe peripheral neuropathy. After
multiple cycles, the patients develop a chronic neuropa-
thy that is characterized by a sensory and motor dys-
function. This chronic neuropathy is a dose-limiting
toxicity and a major clinical problem in oxaliplatin-
based chemotherapy [1].
We previously reported that repeated administration
of oxaliplatin induced cold hyperalgesia in the early
phase and mechanical allodynia in the late phase in rats
[2]. Recently, we reported that spinal NR2B-containing
N-methyl-D-aspartate (NMDA) receptors are involved in
the oxaliplatin-induced mechanical allodynia [3]. The
NMDA receptor antagonists (MK-801 and memantine)
and selective NR2B antagonists (Ro25-6981 and ifenpro-
dil) reverse the oxaliplatin-induced mechanical allodynia.
In addition, an expression of NR2B protein and mRNA
in the rat spinal cord is increased by oxaliplatin on day
25 (late phase).
Activation of the NMDA receptors leads to an
increase in Ca
2+ influx into the cytosol. This increased
Ca
2+ influx initiates cascades of intracellular signaling
events involving Ca
2+ and various protein kinases [4].
Ca
2+/calmodulin dependent protein kinase II (CaMKII)
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Ca
2+ s i g n a l i n g[ 5 ] .A ni n c r e a s ei ni n t r a c e l l u l a rC a
2+
initially activates calmodulin by binding to its Ca
2
+-binding sites, and this interaction induces a change in
the conformation of calmodulin. CaMKII is then
switched to an activated state by exposure to Ca
2
+/calmodulin. Several studies showed that an increase of
CaMKII activation in the spinal cord is involved in per-
sistent pain by nerve injury [6-9] and inflammation
[10,11]. However, the role of CaMKII in the oxaliplatin-
induced mechanical allodynia still remains unclear. In
this study, we investigated the involvement of CaMKII
Figure 1 Effects of KN-93 and KN-92 on oxaliplatin-induced mechanical allodynia in the von Frey test. Rats were treated with oxaliplatin
(4 mg/kg, i.p.) twice a week for 4 weeks (days 1, 2, 8, 9, 15, 16, 22 and 23). We confirmed the incidence of mechanical allodynia on day 24. We
carried out the drug evaluation on the next day. KN-93 (10-50 nmol) or KN-92 (50 nmol) was administered intrathecally. The von Frey test was
performed immediately before (0 min) and at 30, 60, 90 and 120 min after administration. KN-93 (50 nmol) significantly reversed oxaliplatin-
induced mechanical allodynia (A). On the other hand, KN-92 (50 nmol) had no effect on the mechanical allodynia (B).Values are expressed as the
mean ± SEM. of 5-8 animals. **p < 0.01 compared with vehicle (Student’s t-test). †p < 0.05 compared with oxaliplatin alone (one-way ANOVA
followed by Tukey-Kramer post-hoc test).
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explored novel useful therapeutic drugs for the oxalipla-
tin-induced neuropathy.
Results
Effects of KN-93 and KN-92 on Oxaliplatin-induced
mechanical allodynia
Oxaliplatin (4 mg/kg, i.p., twice a week for 4 weeks)
significantly reduced the paw withdrawal thresholds
compared with the vehicle in the von Frey test on day
24 (p < 0.01, Figure 1). Before administration of KN-
93, each group had equivalent paw withdrawal thresh-
olds. The selective CaMKII inhibitor KN-93 (50 nmol,
i.t.) completely reversed the reduction of paw withdra-
wal thresholds by oxaliplatin at 30 min after the
administration (p < 0.05, Figure 1A). This effect of
KN-93 was disappeared within 120 min after the
administration. On the other hand, treatment of KN-
92 (50 nmol, i.t.), the negative control of KN-93, had
no effect on the oxaliplatin-induced mechanical allody-
nia (Figure 1B).
Effect of KN-93 on Oxaliplatin-induced cold hyperalgesia
Oxaliplatin (4 mg/kg, i.p. on days 1 and 2) significantly
increased the number of withdrawal responses to cold
stimulation by acetone spray on day 5 (p < 0.01, Figure
2). Before administration of KN-93, each group had
equivalent number of withdrawal responses. KN-93 (50
nmol, i.t.) did not affect the increase in withdrawal
responses by oxaliplatin.
Effects of KN-93 and Ro 25-6981 on Oxaliplatin-induced
increase in spinal CaMKII phosphorylation
To determine the effect of oxaliplatin on spinal CaM-
KII activity, we investigated the expression of CaMKII
phosphorylation (pCaMKII). The pCaMKII in the
spinal cord of oxaliplatin treated rats significantly
increased compared with that of vehicle-treated rats on
day 25 (p < 0.05, Figure 3). This increased pCaMKII
was blocked by the selective CaMKII inhibitor KN-93
(50 nmol, i.t.) and the selective NR2B antagonist Ro
25-6981 (300 nmol, i.t.). (KN-93: p < 0.05; Ro 25-6981:
p < 0.01, Figure 3).
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Figure 2 Effect of KN-93 on oxaliplatin-induced cold hyperalgesia in the acetone test. Rats were treated with oxaliplatin (4 mg/kg, i.p.) on
days 1 and 2. We confirmed the incidence of cold hyperalgesia on day 5 and we carried out the drug evaluation on the same day. KN-93 (10-
50 nmol) was administered intrathecally. The acetone test was performed immediately before (0 min) and at 30, 60, 90 and 120 min after
administration. KN-93 had no effect on oxaliplatin-induced cold hyperalgesia. Values are expressed as the mean ± SEM. of 7-8 animals. **p< 0.01
compared with vehicle (Student’s t-test).
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mechanical allodynia and increase in CaMKII
phosphorylation
Since trifluoperazine, an antipsychotic drug, inhibits cal-
modulin required for CaMKII phosphorylation [12], we
tested the effect of this compound on the oxaliplatin-
induced mechanical allodynia. Trifluoperazine (0.1 and
0.3 mg/kg, p.o.) significantly reduced the oxaliplatin-
induced mechanical allodynia at 30 min (0.1 mg/kg: p <
0.05; 0.3 mg/kg: p < 0.01) and 120 min (0.3 mg/kg: p <
0.05) after the administration (Figure 4). On the other
hand, trifluoperazine at the effective dose (0.3 mg/kg, p.
o.) had no effect on the paw withdrawal thresholds in
intact rats (Figure 5). Trifluoperazine (0.3 mg/kg, p.o.)
strongly reduced the oxaliplatin-induced increase in
spinal pCaMKII (p < 0.01, Figure 6).
Effect of trifluoperazine on motor coordination
We examined the influence of trifluoperazine on motor
coordination in rota-rod test. At the time before (0 min)
and 30 min after administration of trifluoperazine, there
was no difference in the motor coordination among the
groups-treated with distilled water, trifluoperazine 0.3 mg/
kg or oxaliplatin + trifluoperazine 0.3 mg/kg (Figure 7).
Discussion
In the present study, acute treatment of the CaMKII inhi-
bitor KN-93 reversed the oxaliplatin-induced mechanical
allodynia. KN-93 binds directly to calmodulin-binding
site of CaMKII and inhibits the enzyme activity [13]. KN-
93 also inhibits not only CaMKII but also L-type Ca
2+
channels [14], and therefore there is possibility that the
effect of KN-93 on the mechanical allodynia depends on
blockade of Ca
2+ channels. However, its structural analog
KN-92, which does not inhibit CaMKII but blocks L-type
Ca
2+ channels’ current, did not reverse the oxaliplatin-
induced mechanical allodynia. Moreover, the expression
of pCaMKII significantly increased in the spinal cord of
oxaliplatin-treated rats on day 25, and this increase of
pCaMKII was blocked by KN-93. On the other hand,
KN-93 had no effect on the oxaliplatin-induced cold
hyperalgesia on day 5. These results indicate that the
spinal CaMKII is involved in the oxaliplatin-induced
mechanical allodynia but not cold hyperalgesia.
Recently, we reported that repeated administration of
oxaliplatin increased the expression of NR2B protein
and mRNA in the rat spinal cord on day 25 (late phase)
but not on day 5 (early phase), and Ro 25-6981 reversed
the oxaliplatin-induced mechanical allodynia [3], sug-
gesting the involvement of NR2B-containing NMDA
receptors. These NMDA receptors have been reported
to contribute to development of spinal hyperexcitability
and chronic pain [15-17]. Ca
2+ influx through activated
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Figure 3 Effects of KN-93 and Ro 25-6981 on oxaliplatin-
induced increase in spinal CaMKII phosphorylation. Rats were
treated with oxaliplatin (4 mg/kg, i.p.) twice a week for 4 weeks
(days 1, 2, 8, 9, 15, 16, 22 and 23). The lumbar sections (L4-6) of the
spinal cord were quickly removed at 30 min after administration of
KN-93 (50 nmol, i.t.) or Ro 25-6981 (300 nmol, i.t.) on day 25. CaMKII
phosphorylation (pCaMKII) in the lumbar sections of the spinal cord
was determined by Western blotting. An increase of pCaMKII was
found in the spinal cord of oxaliplatin-treated rats. Acute treatment
with KN-93 (A) and Ro 25-6981 (B) reduced oxaliplatin-induced
increase in the spinal pCaMKII. Values are expressed as mean ± SEM.
of 6-8 animals. *p < 0.05 compared with vehicle, †p < 0.05, ††p <
0.01 compared with oxaliplatin alone (one-way ANOVA followed by
Tukey-Kramer post-hoc test).
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Page 4 of 9NMDA receptors causes multiple intracellular changes
including an activation of CaMKII [18,19], and the
CaMKII co-localizes with NR2B in the nociceptive
regions such as the superficial dorsal horn [20]. Further-
more, NR2B mutation, which causes a lower increase in
intracellular Ca
2+ concentration by glutamate stimula-
tion, leads to the reduction of spinal CaMKII phosphor-
ylation in the neuropathic pain model [8,9]. In our
present study, we found that the increase of pCaMKII in
the spinal cord of oxaliplatin-treated rats was blocked by
Ro 25-6981, the selective NR2B antagonist. Therefore,
oxaliplatin may induce the CaMKII activation by
increasing in the expression of NR2B-containing NMDA
receptors. These findings indicate an important role of
CaMKII as a downstream of NR2B-containing NMDA
receptors in pain states.
In this study, we confirmed an inhibition of CaMKII
phosphorylation by trifluoperazine, which inhibits cal-
modulin required for CaMKII activation [12].
Furthermore, we found that trifluoperazine dose-depen-
dently reduced the oxaliplatin-induced mechanical allo-
dynia. Previous studies showed that trifluoperazine
reversed complete Freund’s adjuvant-induced inflamma-
tory pain and spinal nerve ligation-induced neuropathic
pain in mice [7,11]. On the other hand, we observed
that trifluoperazine at the effective dose (0.3 mg/kg) had
no effect on the paw withdrawal thresholds in intact
rats. In addition, trifluoperazine at the same dose did
not affect the motor coordination in rota-rod test in
intact and oxaliplatin-treated rats. Ye et al. [21] reported
that trifluoperazine (0.125-0.5 mg/kg, i.p.) did not affect
spontaneous locomotion in rats. Bhargava and Chandra
[22] reported that ED50 (i.p.) of suppression of the con-
ditioned response, an index of tranquilizing effect, is
0.58 mg/kg. Therefore, it is unlikely that the inhibitory
effect of trifluoperazine on the oxaliplatin-induced pain
behavior is due to its motor dysfunction or sedative
effect. Taken together, the inhibitory effect of
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Figure 4 Effect of trifluoperazine on oxaliplatin-induced mechanical allodynia in the von Frey test. Rats were treated with oxaliplatin (4
mg/kg, i.p.) twice a week for 4 weeks (days 1, 2, 8, 9, 15, 16, 22 and 23). We confirmed the incidence of mechanical allodynia on day 24. We
carried out the drug evaluation on the next day. Trifluoperazine (0.05-0.3 mg/kg) was administered orally. The von Frey test was performed
immediately before (0 min) and at 30, 120 and 240 min after administration of trifluoperazine. Trifluoperazine (0.1 and 0.3 mg/kg) significantly
reversed oxaliplatin-induced mechanical allodynia. Values are expressed as the mean ± SEM. of 8 animals. **p < 0.01 compared with vehicle, †p
< 0.05, ††p < 0.01 compared with oxaliplatin alone (one-way ANOVA followed by Tukey-Kramer post-hoc test).
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Page 5 of 9trifluoperazine on spinal CaMKII activity may be
involved in the reduction of pain behavior, and low
doses of trifluoperazine may be useful for the treatment
of the oxaliplatin-induced neuropathy.
Conclusions
Our results indicate that repeated administration of oxali-
platin increases spinal CaMKII activity. This increase of
CaMKII activation was reversed by intrathecal injection of
the selective CaMKII inhibitor and the selective NR2B
antagonist. This CaMKII activation may contribute to the
incidence of mechanical allodynia. Furthermore, the selec-
tive CaMKII inhibitor and the selective NR2B antagonist
reduced the oxaliplatin-induced pain behavior. In addition,
trifluoperazine reduced the oxaliplatin-induced mechani-
cal allodynia and CaMKII activation. These results suggest
that inhibition of CaMKII or NMDA-CaMKII pathway
provides a novel therapeutic target for the treatment of
the oxaliplatin-induced peripheral neuropathy.
Methods
Animals
Male Sprague-Dawley rats weighing 200-250 g (Kyudo
Co., Saga, Japan) were used in the present study. Ani-
mals were housed in groups of four to five per cage,
with lights on from 7:00 to 19:00 h. Animals had free
access to food and water in their home cages. All
experiments were approved by the Experimental Animal
Care and Use Committee of Kyushu University accord-
ing to the National Institutes of Health guidelines, and
we followed International Association for the Study of
Pain (IASP) Committee for Research and Ethical Issues
guidelines for animal research [23].
Drugs
Oxaliplatin (Elplat
®) was obtained from Yakult Co., Ltd.
(Tokyo, Japan). KN-93, Ro 25-6981 hydrochloride
hydrate and trifluoperazine dihydrochloride were pur-
chased from Sigma-Aldrich (Missouri, USA). KN-92 was
purchased from Calbiochem (California, USA). Oxalipla-
tin was dissolved in 5% glucose solution. The vehicle-
treated rats were injected with 5% glucose solution. KN-
93, KN-92 and Ro 25-6981 were dissolved in 100%
dimethyl sulfoxide (DMSO). Trifluoperazine was dis-
solved in distilled water. The doses of these drugs were
chosen based on previous reports [2,3,7].
Production of neuropathy
Mechanical allodynia and cold hyperalgesia were
induced according to the method described previously
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Figure 5 Effect of trifluoperazine on mechanical nociceptive threshold in the von Frey test. Trifluoperazine (0.3 mg/kg) was administered
orally in intact rats. The von Frey test was performed immediately before (0 min) and at 30, 120 and 240 min after administration of
trifluoperazine. Trifluoperazine did not affect mechanical nociceptive threshold in intact rats. Values are expressed as the mean ± SEM. of 8
animals. No statistical difference was identified (one-way ANOVA followed by Tukey-Kramer post-hoc test).
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Page 6 of 9[24]. Oxaliplatin (4 mg/kg) or vehicle (5% glucose solu-
tion) was administered i.p. twice a week for 4 weeks (on
days 1, 2, 8, 9, 15, 16, 22 and 23). The volume of vehicle
or drug solution injected was 1 mL/kg for all drugs.
Behavioral studies
Behavioral test was performed blindly with respect to
drug administration.
von Frey test for mechanical allodynia
The mechanical allodynia was assessed by von Frey test.
Each rat was placed in a clear plastic box (20 × 17 × 13
cm) with a wire mesh floor and allowed to habituate for
30 min prior to testing. von Frey filaments (The Touch
Test Sensory Evaluator Set; Linton Instrumentation,
Norfolk, UK) ranging from 1- to 15-g bending force
were applied to the midplantar skin of each hind paw
six times, with each application held for 6 s. The paw
withdrawal threshold was determined by a modified up-
down method [25].
Acetone test for cold hyperalgesia
The cold hyperalgesia was assessed by acetone test.
Each rat was placed in a clear plastic box (20 × 17 ×
13 cm) with a wire mesh floor and allowed to habitu-
ate for 30 min prior to testing. Fifty microliters of
acetone (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) was sprayed onto the plantar skin of each hind
paw 3 times, and the number of withdrawal responses
was counted for 40 s from the start of the acetone
spray.
Rota-rod test for motor coordination
The rota-rod test was performed to investigate the
change of motor coordination. Rats were placed on a
rotating rod (Muromachi Kikai Co., Ltd., Tokyo, Japan)
and the latency to falling was measured for up to 2 min
according to the method described previously [26]. The
test was performed three times, and the rotating speed
was 10 rpm.
Effects of KN-93, KN-92 and trifluoperazine on
Oxaliplatin-induced mechanical allodynia
We confirmed the incidence of mechanical allodynia in
the von Frey test on day 24. We carried out the drug
evaluation on the next day. KN-93 (10-50 nmol) or KN-
92 (50 nmol) was administered i.t. injection by direct
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Figure 6 Effect of trifluoperazine on oxaliplatin-induced
increase of spinal CaMKII phosphorylation. Rats were treated
with oxaliplatin (4 mg/kg, i.p.) twice a week for 4 weeks (days 1, 2,
8, 9, 15, 16, 22 and 23). The lumbar sections (L4-6) of the spinal cord
were quickly removed at 30 min after administration of
trifluoperazine (0.3 mg/kg, p.o.) on day 25. CaMKII phosphorylation
(pCaMKII) in the lumbar sections of the spinal cord was determined
by Western blotting. An increase of pCaMKII was found in the spinal
cord of oxaliplatin-treated rats. Acute treatment with trifluoperazine
reduced oxaliplatin-induced increase in the spinal pCaMKII. Values
are expressed as mean ± SEM. of 6-7 animals. *p < 0.05 compared
with vehicle, ††p < 0.01 compared with oxaliplatin alone by Tukey-
Kramer post-hoc test.
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Figure 7 Effect of trifluoperazine on motor coordination in the
rota-rod test. Trifluoperazine (0.3 mg/kg) was administered orally in
intact and oxaliplatin-treated rats. The rota-rod test was performed
immediately before (0 min) and at 30 min after administration of
trifluoperazine. Trifluoperazine did not affect motor coordination in
intact and oxaliplatin-treated rats. Values are expressed as the mean
± SEM. of 8-11 animals. No statistical difference was identified (one-
way ANOVA followed by Tukey-Kramer post-hoc test).
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test was performed immediately before (0 min) and at
30, 60, 90 and 120 min after administration of the
drugs. Trifluoperazine (0.05-0.3 mg/kg) was adminis-
tered p.o. The von Frey test was performed immediately
before (0 min) and at 30, 120 and 240 min after oral
administration of trifluoperazine.
Effect of KN-93 on Oxaliplatin-induced cold hyperalgesia
We confirmed the incidence of cold hyperalgesia in the
acetone test on day 5. KN-93 (10-50 nmol) was adminis-
tered i.t. injection by direct lumbar puncture in a
volume of 50 µL. The acetone test was performed
immediately before (0 min) and at 30, 60, 90 and 120
min after administration of the drug.
Effect of trifluoperazine on mechanical nociceptive
threshold
We investigated the effect of trifluoperazine on the
mechanical nociceptive threshold in the von Frey test.
Trifluoperazine (0.3 mg/kg) was administered p.o. in
intact rats. The von Frey test was performed immedi-
ately before (0 min) and at 30, 120 and 240 min after
oral administration of trifluoperazine.
Effect of trifluoperazine on motor coordination
We investigated the effect of trifluoperazine on the
motor coordination in the rota-rod test. Trifluoperazine
(0.3 mg/kg) was administered p.o. in intact and oxalipla-
tin-treated rats. The rota-rod test was performed imme-
diately before (0 min) and at 30 min after oral
administration of trifluoperazine.
Western blotting analysis
The lumbar sections (L4-6) of the spinal cord were
quickly removed at 30 min after administration of KN-
93 (50 nmol, i.t.), Ro 25-6981 (300 nmol, i.t.) or trifluo-
perazine (0.3 mg/kg, p.o.) on day 25. The tissues were
homogenized in a solubilization buffer containing 20
mM Tris-HCl (pH 7.4, 2 mM EDTA, 0.5 mM EGTA, 10
mM NaF, 1 mM Na3VO4, 1 mM PMSF, 0.32 M Sucrose,
2 mg/ml aprotinine, 2 mg/ml leupeptin), and the homo-
genates were subjected to 12.5% SDS-PAGE, and pro-
teins were transferred electrophoretically to PVDF
membranes. The membranes were blocked in Tris-buf-
fered saline Tween-20 (TBST) containing 5% BSA
(Sigma-Aldrich) for an additional 1 h at room tempera-
ture with agitation. The membrane was incubated over-
n i g h ta t4 ° Cw i t hm o u s ep olyclonal anti-CaMKIIa
antibody or rabbit polyclonal anti-(Thr286)pCaMKII
(1:5000; Santa Cruz Biotechnology, California, USA) and
then incubated for 1 h with corresponding horseradish
peroxidase conjugate secondary antibodies (1:5000; Jack-
son Immuno Research Laboratories, Inc., PA, USA). The
immunoreactivity was detected using Enhanced Chemi-
luminescence (Perkin Elmer, Massachusetts, USA).
Ratios of the optical densities of pCaMKII to those of
CaMKII were calculated for each sample.
Data analysis
Values were expressed as the means ± SEM. The values
were analyzed by the Student’s t-test or one-way analysis
of variance (ANOVA) followed by the Tukey-Kramer
post-hoc test (StatView; Abacus Concepts, Berkely, CA,
USA) to determine differences among the groups. A p
value of less than 0.05 is considered as statistically
significant.
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